Greenwich Net Tangible Assets from 2010 to 2026
| GLSI Stock | USD 24.88 2.18 9.60% |
Net Tangible Assets | First Reported 2010-12-31 | Previous Quarter 30.8 M | Current Value 32.4 M | Quarterly Volatility 19.2 M |
Check Greenwich Lifesciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Greenwich Lifesciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 4 K, Other Operating Expenses of 19.3 M or Research Development of 15.6 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 54.5. Greenwich financial statements analysis is a perfect complement when working with Greenwich Lifesciences Valuation or Volatility modules.
Greenwich | Net Tangible Assets | Build AI portfolio with Greenwich Stock |
The Net Tangible Assets trend for Greenwich Lifesciences offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Greenwich Lifesciences is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest Greenwich Lifesciences' Net Tangible Assets Growth Pattern
Below is the plot of the Net Tangible Assets of Greenwich Lifesciences over the last few years. It is the total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company. Greenwich Lifesciences' Net Tangible Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Greenwich Lifesciences' overall financial position and show how it may be relating to other accounts over time.
| Net Tangible Assets | 10 Years Trend |
|
Net Tangible Assets |
| Timeline |
Greenwich Net Tangible Assets Regression Statistics
| Arithmetic Mean | 6,200,158 | |
| Geometric Mean | 13,748,971 | |
| Coefficient Of Variation | 310.11 | |
| Mean Deviation | 18,201,904 | |
| Median | (10,148,785) | |
| Standard Deviation | 19,227,180 | |
| Sample Variance | 369.7T | |
| Range | 42.5M | |
| R-Value | 0.89 | |
| Mean Square Error | 84.5T | |
| R-Squared | 0.79 | |
| Slope | 3,374,805 | |
| Total Sum of Squares | 5915T |
Greenwich Net Tangible Assets History
About Greenwich Lifesciences Financial Statements
Investors use fundamental indicators, such as Greenwich Lifesciences' Net Tangible Assets, to determine how well the company is positioned to perform in the future. Although Greenwich Lifesciences' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
| Last Reported | Projected for Next Year | ||
| Net Tangible Assets | 30.8 M | 32.4 M |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out the analysis of Greenwich Lifesciences Correlation against competitors. For more detail on how to invest in Greenwich Stock please use our How to Invest in Greenwich Lifesciences guide.You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is there potential for Biotechnology market expansion? Will Greenwich introduce new products? Factors like these will boost the valuation of Greenwich Lifesciences. Market participants price Greenwich higher when confident in its future expansion prospects. Understanding fair value requires weighing current performance against future potential. All the valuation information about Greenwich Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Investors evaluate Greenwich Lifesciences using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Greenwich Lifesciences' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. External factors like market trends, sector rotation, and investor psychology can cause Greenwich Lifesciences' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Greenwich Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Greenwich Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Greenwich Lifesciences' market price signifies the transaction level at which participants voluntarily complete trades.